EICHORCondition: Advanced Solid Malignancies · Sponsor: AstraZeneca
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurred/progressed.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
AstraZeneca Breast Cancer Study Locator Service · 1-877-400-4656 · az-bcsl@careboxhealth.com
Always discuss trial participation with your own doctor first.
| Research Site | La Jolla, California, United States | Withdrawn |
| Research Site | Los Angeles, California, United States | Recruiting |
| Research Site | San Francisco, California, United States | Recruiting |
| Research Site | Chicago, Illinois, United States | Recruiting |
| Research Site | Boston, Massachusetts, United States | Recruiting |
| Research Site | New York, New York, United States | Recruiting |
| Research Site | New York, New York, United States | Recruiting |
| Research Site | Portland, Oregon, United States | Completed |
| Research Site | Houston, Texas, United States | Recruiting |
| Research Site | San Antonio, Texas, United States | Recruiting |
| Research Site | Richmond, Virginia, United States | Withdrawn |
| Research Site | Darlinghurst, Australia | Recruiting |
+ 20 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05417594